Posts

Posted on

Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH

– Pegcetacoplan demonstrated statistical superiority on the co-primary endpoints of haemoglobin stabilisation (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of care, which did not include complement inhibitors, at week 26

– Mean haemoglobin levels in the pegcetacoplan group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019)

– 91 per cent of patients on pegcetacoplan were transfusion free compared to 22 per cent on standard of care (p<0.0001)

– The safety profile of pegcetacoplan was consistent with previous studies

PR Newswire

STOCKHOLM, May 25, 2021 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (GLOBE NEWSWIRE) today reported positive top-line results from the phase 3 PRINCE study evaluating the efficacy and safety of pegcetacoplan in adults with paroxysmal nocturnal haemoglobinuria (PNH) who are treatment naïve, meaning they had not received a complement inhibitor within three months before entering the study.

Pegcetacoplan demonstrated statistical superiority on the co-primary endpoints of haemoglobin stabilization and reduction in lactate dehydrogenase (LDH) compared to standard of care, which did not include complement inhibitors, at week 26.

  • 86 per cent of pegcetacoplan treated patients achieved haemoglobin stabilisation compared to 0 per cent of patients on standard of care (p<0.0001). Haemoglobin stabilisation was defined as an avoidance of a >1 g/dL decrease in haemoglobin levels in the absence of transfusions.
  • Mean LDH in the pegcetacoplan group decreased by 90 per cent from a baseline of 2151 U/L [9.5x upper limit of normal (ULN)] to 211 U/L, which is within the normal range, compared to a 14 per cent reduction on standard of care from a baseline of 1946 U/L (8.6x ULN) to 1681 U/L (7.4x ULN) (p<0.0001).

“The positive PRINCE data showed that pegcetacoplan provided clinically meaningful improvements across multiple measures that are important for patients and build on our recent FDA approval of pegcetacoplan in PNH,” said Federico Grossi, M.D., Ph.D., chief medical officer, Apellis. “Combined with previous studies, these results emphasize the potential of pegcetacoplan to provide disease control for all adults with PNH regardless of prior treatment.”

Pegcetacoplan also achieved statistical superiority on several secondary endpoints, including improvements in haemoglobin levels and transfusion avoidance, compared to standard of care, which did not include complement inhibitors.

  • Mean haemoglobin levels in the pegcetacoplan group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from a baseline of 8.7 g/dL to 9.4 g/dL on standard of care (p=0.0019).
  • 91 per cent of patients on pegcetacoplan were transfusion free compared to 22 per cent on standard of care (p<0.0001).

The safety profile of pegcetacoplan was consistent with previous studies. At week 26, 9 per cent of patients in the pegcetacoplan group experienced a serious adverse event (SAE) compared to 17 per cent on standard of care. One death was reported in each group, and neither were related to treatment. No cases of meningitis or thrombosis were reported in either group. The most common adverse events reported during the study in the pegcetacoplan and standard of care groups, respectively, were injection site reaction (30 per cent vs. 0 per cent), hypokalemia (13 per cent vs. 11 per cent), and fever (9 per cent vs. 0 per cent).

“The PRINCE study results reinforce the efficacy and safety profile of pegcetacoplan in PNH,” said Ravi Rao, Head of Research & Development and Chief Medical Officer at Sobi. “Our hope is to contribute to an improvement of care, and to make a difference in the lives of people with this rare blood disease.”

Detailed results from the PRINCE study will be presented at medical congresses.

About the PRINCE study

The PRINCE study (NCT04085601) is a 2:1 (pegcetacoplan: standard of care) randomized, multi-center, open-label, controlled phase 3 study in 53 treatment-naïve adults with paroxysmal nocturnal haemoglobinuria (PNH). The primary objective of this study was to establish the efficacy and safety of pegcetacoplan in patients who have not received treatment with any complement inhibitor within three months prior to screening. During the 26-week randomized, controlled period, patients received either 1080 mg of pegcetacoplan twice weekly or standard of care therapy, which did not include complement inhibitors. Patients in the standard of care group had the option to escape to the pegcetacoplan group if their haemoglobin decreased 2 g/dL or more from their baseline value.

About pegcetacoplan

Pegcetacoplan is an investigational therapy targeting C3, the central protein in the complement cascade. It acts proximally in the complement cascade controlling both C3bmediated extravascular haemolysis and terminal complementmediated intravascular haemolysis. Pegcetacoplan is being evaluated in several clinical studies across haematology, ophthalmology, nephrology, and neurology. In May 2021, pegcetacoplan was approved as EMPAVELITM in the US for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH). The marketing authorisation application for pegcetacoplan for paroxysmal nocturnal haemoglobinuria (PNH) is under review by the European Medicines Agency (EMA). Pegcetacoplan was also granted Fast Track designation by the FDA for the treatment of geographic atrophy and received orphan drug designation for the treatment of C3 glomerulopathy by the FDA and EMA. For additional information regarding pegcetacoplan clinical studies, visit apellis.com/our-science/clinical-trials.

About Paroxysmal Nocturnal Haemoglobinuria (PNH)

PNH is a rare, chronic, life-threatening blood disorder characterized by the destruction of oxygen-carrying red blood cells through extravascular and intravascular haemolysis. Persistently low haemoglobin can result in frequent transfusions and debilitating symptoms such as severe fatigue, haemoglobinuria and difficulty breathing (dyspnea).

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within haematology, ophthalmology, nephrology, and neurology. For more information, please visit http://apellis.com.

About Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, Middle East and Asia. In 2020, Sobi’s revenues amounted to SEK 15.3 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 13:00 CEST on 25 May 2021.

For more information, please contact

Paula Treutiger, Head of Communication & Investor Relations

+ 46 733 666 599

[email protected]

Maria Kruse, Corporate Communication & Investor Relations

+ 46 767 248 830

[email protected]

Apellis

Media:

Lissa Pavluk

[email protected]  

617.977.6764

Investors:

Argot Partners

[email protected]

212.600.1902

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/positive-top-line-results-from-the-phase-3-prince-study-of-pegcetacoplan-in-treatment-naive-patients,c3353197

The following files are available for download:

https://mb.cision.com/Main/14266/3353197/1422180.pdf

Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH

Cision View original content:http://www.prnewswire.com/news-releases/positive-top-line-results-from-the-phase-3-prince-study-of-pegcetacoplan-in-treatment-naive-patients-with-pnh-301298694.html

SOURCE Swedish Orphan Biovitrum AB

Posted on

Inovalon Receives Key Patent Award for On-Demand Real-Time Patient-Specific Data Aggregation and Analysis

Significant IP Award Highlighting Inovalon’s Industry-Leading Technology

BOWIE, Md., May 25, 2021 (GLOBE NEWSWIRE) — Inovalon (NASDAQ: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that it has been awarded a significant patent for its capability to aggregate healthcare data from across the healthcare ecosystem, apply requested analytics, and make the results available on demand in real time.

U.S. Patent No. 11,011,256, for the “Systems and Method for Providing an On-Demand Real-Time Patient-Specific Data Analysis Computing Platform” adds to Inovalon’s portfolio of intellectual property protection as the Company continues to bring industry-leading innovation and capabilities to the marketplace for its customers and the individuals they serve.

The capabilities covered under this patent provide for on-demand healthcare Data-as-a-Service (DaaS) and Analytics-as-a-Service (AaaS) in real time at the patient-specific level and is one of the elements of intellectual property empowering the Inovalon DataStream® API technology announced on September 24, 2020 (link here) and a wide array of application enhancements within the Inovalon ONE® Platform portfolio.

Recognizing that demand for highly complex healthcare data and analytics would increasingly be requested by applications and mobile devices with limited resident data and compute capability, Inovalon began work in 2015 on the architecture needed to solve for the multiple barriers of execution inherent in healthcare.

  • The first barrier being the disparate nature of healthcare data. Most people receive medical care through different affiliations (e.g., health plans, employers, and unions) and at multiple locations (e.g., physician offices, hospitals, clinics, radiology centers, laboratory centers, and pharmacies) that often change as people move to a different geography, change jobs, retire, or travel for work or leisure. Because of this, the typical person’s historical and ongoing healthcare data can reside in dozens of disparate systems (e.g., EHRs, claims systems, laboratory systems, and pharmacy systems).
  • The second barrier originating from the “messy” nature of healthcare data, necessitating significant capabilities of normalization and processing of structured and non-structured data to enable the interpretation of data from thousands of differing sources – each of which have tendencies to undergo evolving shifts in both discrete data element nature and in the subjective healthcare practice nature.
  • The third barrier comes from the many laws and regulations governing healthcare data access and use requiring there to be a known use or need for accessing a person’s healthcare data and a requirement to access a minimum amount needed, thus making untenable the option of overcoming the complexity of dislocated data by gathering the entirety of data in advance of any specific need.
  • And the fourth barrier originates from the fact that the demand for accessing and applying patient-specific data and its analytical derivatives was expected to emanate from relatively small and mobile devices, platforms which themselves have limited data storage, compute, and bandwidth capacity.

These barriers necessitated the design of systems that would enable extremely widespread connectivity across thousands of primary data sources to overcome barriers of healthcare data’s disparate nature; employ sophisticated data integrity and analytical capability to enable data ingestion, normalization, and conversion from non-structured to structured data; provide for real-time response times thus granting the flexibility to be called upon once a patient’s need and use have been identified to assure data regulatory compliance; and provide for large scale compute and storage independent from the location of the requesting platform. Multiple Modules and micro services of the Inovalon ONE® Platform come together to overcome these barriers, bringing to life the ability for any authorized device, application, or platform to make a specific request pertaining to a specific patient, and receive the requested data or analytical result on demand and in real time. The types of data and menu of analytical questions able to be called on demand are extensive and can be customized by Inovalon’s customers.

“We see a world where the real-time availability of data and its analysis dramatically advances the speed of discovery, diagnosis, treatment, effectiveness, access, and efficiency of healthcare everywhere,” said Keith Dunleavy, M.D., Inovalon’s chief executive officer and chairman of the board. “By bringing together the unique technologies needed to realize these transformative changes, we empower our customers to achieve their critical goals on behalf of the patients they care for. We are committed and proud to continue advancing the technologies needed to support these important goals.”

The intellectual property covered under this patent and others within Inovalon’s intellectual property portfolio support capabilities within the Inovalon ONE® Platform.

About the Inovalon ONE

®

Platform

The Inovalon ONE® Platform is an integrated cloud-based platform of nearly 100 individual proprietary technology toolsets and deep data assets able to be rapidly configured to empower the operationalization of large-scale, data-driven healthcare initiatives. Each proprietary technology toolset, referred to as a Module, is informed by the data of billions of medical events within Inovalon’s proprietary datasets. Combinations of Modules are configured to empower highly differentiated solutions for client needs quickly and in a highly scalable fashion. The flexibility of the Platform’s modular design enables clients to integrate the Platform capabilities with their own internal capabilities or other third-party solutions. The Platform brings to the marketplace a highly extensible, national-scale capability to interconnect with the healthcare ecosystem on a massive scale, aggregate and analyze data in petabyte volumes, arrive at sophisticated insights in real time, and drive meaningful impact wherever it is analytically identified best to intervene, and intuitively visualize data and information to inform business strategy and execution.

About Inovalon

Inovalon is a leading provider of cloud-based platforms empowering data-driven healthcare. Through the Inovalon ONE® Platform, Inovalon brings to the marketplace a national-scale capability to interconnect with the healthcare ecosystem, aggregate and analyze data in real time, and empower the application of resulting insights to drive meaningful impact at the point of care. Leveraging its Platform, unparalleled proprietary datasets, and industry-leading subject matter expertise, Inovalon enables better care, efficiency, and financial performance across the healthcare ecosystem. From health plans and provider organizations, to pharmaceutical, medical device, and diagnostics companies, Inovalon’s unique achievement of value is delivered through the effective progression of “Turning Data into Insight, and Insight into Action®.” Supporting thousands of clients, including all 25 of the top 25 U.S. health plans, all 25 of the top 25 global pharma companies, 24 of the top 25 U.S. healthcare provider systems, and many of the leading pharmacy organizations, device manufacturers, and other healthcare industry constituents, Inovalon’s technology platforms and analytics are informed by data pertaining to more than one million physicians, 580,000 clinical facilities, 336 million Americans, and 62 billion medical events. For more information, visit www.inovalon.com.

Contacts:

Kim Collins
Phone: 301-809-4000 x1473        
[email protected]

Hulus Alpay
Vice President, Investor Relations
[email protected]
301-809-4000 x1237



Posted on

Canapar Acquired by RAMM Pharma

Acquisition opens new opportunities for both companies in European and South American markets

RAGUSA, Italy, May 25, 2021 (GLOBE NEWSWIRE) — Canapar Corp. (“Canapar”) today announced a definitive agreement with RAMM Pharma Corp. (including its wholly owned subsidiaries, “RAMM”) for RAMM to acquire all the remaining common shares of Canapar. In exchange, Canapar will receive approximately 21 million common shares in RAMM for a total purchase price of approximately CA$26.2 million. Under the agreement, Canapar shareholders will receive approximately 0.54 RAMM shares for each share held in Canapar. This transaction follows RAMM’s acquisition of 49% of common shares in Canapar in December 2020.

“We expect that deepening our partnership with RAMM further builds Canapar’s capacity to grow its market share in the European and global cannabis markets,” said Sergio Martines, CEO, Canapar. “From our high-performance facility in Ragusa, Italy we aim to manufacture and distribute brands from both the RAMM and Canapar portfolios, using our expertise in extraction, ability to produce at scale, and combined working capital position of approximately $27 million to market world-class CBD products.”

Following the acquisition and certain approvals from European and Italian regulators, Canapar expects to leverage RAMM’s expertise in cannabinoid pharmaceuticals to deepen its product portfolio. This includes exploring the expansion of NettaVet 10%, a CBD formulation for veterinary medicine recently approved by Uruguayan government, to the European market, as well as the expansion of Marishanti, Canapar’s wellness brand, to South American markets.

“This is a transformational acquisition for RAMM as it further strengthens our presence as a leader in the European cannabis market with a prominent and differentiated global cannabis platform,” stated Jack Burnett, Chief Executive Officer of RAMM.

Upon closing of the transaction, Sergio Martines will be appointed to RAMM’s board of directors. Martines will also be appointed to RAMM’s management team and will remain in his role as CEO of Canapar. The transaction will take effect after a special meeting of RAMM’s shareholders on June 11, 2021.

About Canapar Corp.

Canapar with its wholly owned subsidiaries in Europe is an Italy-based manufacturer and processor of CBD oil, distillates and isolates, which are increasingly used as an input into new commercial products in the health and wellness industries. Canapar had secured more than 1,000 hectares of hemp through its outsource farming model and entered into an academic partnership with the University of Catania’s Department of Agriculture. Canapar is also advancing its CBD extraction and processing capabilities through its new facility and is expecting to transform 450 metric tons of hemp biomass annually into CBD isolates and derivative products for distribution in Europe following the commissioning of its extraction machinery. With demand for products that contain natural active ingredients derived from plant extracts increasing significantly, Canapar plans on developing CBD-infused cosmetics, skincare, and beauty products for the Italian cosmetics market, which is the fourth largest such market in Europe, as well as the global market, which provides strong demand for “Made in Italy” brands.

A video overview of Canapar’s operations can be found on-line, and additional information about Canapar and can be found on its website at https://www.canapar.com/.

About RAMM Pharma Corp.

Led by renowned cannabis industry experts and backed by successful pioneers in the cannabis sector, RAMM is a leader in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. Founded in 1988 in Montevideo, Uruguay, the Company is a well established pharmaceutical and medical product business that has developed medically registered and approved plant-derived cannabinoid pharmaceutical products. The Company currently has multiple approved and registered products that have been authorized for sale in Uruguay and compassionate use in several Latin American countries, as well as a pipeline of new products in various stages of approval and development produced in the Company’s state of the art Good Manufacturing Practice (GMP) certified cannabis formulation facility. Further to its industry leading activities in the cannabis sector, the Company operates a successful pharmaceutical, cosmetic and nutraceutical product development and medical services business which has been servicing the local market for 30 years.

RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Additional information about the Company is available at www.RAMMpharma.com.

For further information, please contact:

Press Office
Rossana Caruso
[email protected]
+39 393 8950322



Posted on

IIROC Trading Halt – EGM

Canada NewsWire

VANCOUVER, BC, May 25, 2021 /CNW/ – The following issues have been halted by IIROC:

Company: Engold Mines Ltd.

TSX-Venture Symbol: EGM

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 7:45 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on

Yadea Shines with Cutting-Edge Electric Two-Wheeler Technologies at Wuxi International Electric Vehicle Exhibition

PR Newswire

WUXI, China, May 25, 2021 /PRNewswire/ — Yadea Technology Group Co., Ltd. (“Yadea”, 01585.HK), a leading two-wheel electric vehicle brand, exhibited a series of products and stole the show with its innovative technologies, such as wireless charging and smart voice interaction, at the 15th Wuxi International Electric Vehicle Exhibition on May 20 in Wuxi, China.

The global electric two-wheeler industry has entered a state of hyperdrive, spurred on by a heightened focus on environmental protection, development of new policies, and shifting attitudes to public transportation because of the pandemic. Two wheelers are now going electric faster than any other segment of road transportation, and electric two-wheelers account for 35 percent of new sales globally. As consumer demand surges, a revolution is well underway — and Yadea is leading the charge.

“Yadea is committed to the research and development of cutting-edge technologies in the electric two-wheeler industry, and we are proud to exhibit these at the Wuxi International Electric Vehicle Exhibition. We have already established an advantage in hardware with our previous investments into motors, batteries, chargers and supply chain. As we look to the future, we turn our focus to gaining a technological advantage through smart experiences, product positioning, user operation, automation and more,” said Aska Zeng, General Manager of Yadea.

In recent years, Yadea has expanded its R&D capabilities to strengthen its competitive advantage in electric two-wheeler technologies, increase production efficiency, and achieve results that surpass others in the industry. Its current facilities include CNAS national-level laboratories, product technology research institutes, smart and product R&D centers, power research institutes and more.

The payoff of these investments was evident during the exhibition, as Yadea showcased its newly upgraded advanced Smart series. These vehicles have reached new heights with a new navigation system, improved call functions, music entertainment and voice interaction — revolutionizing the smart travel market. Yadea has also realized the integration and connection of multiple information systems using cloud deployment and modular configuration, becoming the first two-wheeler brand to realize China’s Internet Plus plan.

Furthermore, Yadea highlighted the benefits of its “Global Multiplication” strategy introduced late last year. This model champions the upgrade of the entire industry with premium brands, better products and services, and newer models with Yadea’s advantages only poised to grow — all while supporting United Nations Sustainable Development Goals for sustainable transport.

As a result of its strategy, the company’s graphene battery, integrated side-mounted motor, adaptive motor, intelligent control system and other technologies have garnered recognition worldwide. This has led to Yadea establishing a partnership with the FIFA World Cup, and the official launch of its global brand in April. Yadea’s products are now sold in 88 countries with more than 35,000 retail stores worldwide.

Looking ahead, Yadea will continue to harness its ever-increasing industry leadership to herald the electric mobility revolution and pursue new trends in R&D — ultimately becoming the foundation for the continuous advancement of two-wheeler transportation.

About Yadea

Yadea is a global leader in developing and manufacturing electric two-wheel vehicles including electric motorcycles, electric mopeds, electric bicycles and electric kick scooters. Yadea’s mission is to use its market leadership to inspire a movement towards greener travel solutions and its vision is to create world-leading electric vehicle solutions by building innovative technologies that meet and exceed international standards for safety and quality.

For more information, visit our:
Official Website: https://www.yadea.com/
Facebook:  https://www.facebook.com/Yadea.Official
Instagram:  https://www.instagram.com/YADEA.GLOBAL/    
Twitter:  https://twitter.com/YadeaGlobal

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/yadea-shines-with-cutting-edge-electric-two-wheeler-technologies-at-wuxi-international-electric-vehicle-exhibition-301298688.html

SOURCE YADEA

Posted on

(SY) Alert: Did You Lose Money on Your So-Young Investment? Contact Johnson Fistel Regarding Investigation

PR Newswire

SAN DIEGO, May 25, 2021 /PRNewswire/ — Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against So-Young International Inc. (NASDAQ: SY) (“So-Young”) for violations of federal securities laws. 

So-Young operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments. Its platform enables users to discover content and share their own experience on medical aesthetics procedures and leads users to reserve treatment services from medical aesthetic service providers for offline treatment in the People’s Republic of China and internationally.

So-Young, went public in May 2019, at $13.80 a share, raising $179,400,000 in new capital.  However, since the IPO, So-Young stock has tumbled, on May 24, 2021, the stock closed at $9.14.

On May 6, 2021, Blue Orca Capital published a report regarding So-Young, wherein the report detailed a series of alarming red flags about So-Young. Specifically, the report stated, that the Company “estimate[s] that SY exaggerates the bookings from these clinics by at least 4-5x during the period we monitored. We think this indicates, persuasively, that SY is inflating both the popularity of its platform and its reported revenues.”

The investigation focuses on whether the Company issued false and misleading statements and failed to disclose information pertinent to investors.

If you have information that could assist in this investigation, or if you are a So-Young shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP
Jim Baker, 619-814-4471 
[email protected]

[Click here to join this action]

 

Cision View original content:http://www.prnewswire.com/news-releases/sy-alert-did-you-lose-money-on-your-so-young-investment-contact-johnson-fistel-regarding-investigation-301298687.html

SOURCE Johnson Fistel, LLP

Posted on

Fat Tail Risk ETF To Launch on the NYSE

Portfolio Offers Investors a Way to Protect Against Market Declines

PR Newswire

NEW YORK, May 25, 2021 /PRNewswire/ — Fat Tail Risk ETF (NYSE: FATT) will start trading on the New York Stock Exchange today. FATT offers investors a way to protect portfolios against large market declines. 

FATT is designed to make money during bull markets while still being able to make money during major market declines.

 “Markets move faster than ever before, and the Covid crisis showed us that bear markets can happen over months now instead of years,” says Matthew Tuttle, Chief Executive Officer and Chief Investment Officer of Tuttle Capital Management LLC (“TCM”), who serves as the Adviser to FATT. “Traditional investments can’t be relied upon to protect from the next market decline, and traditional tail risk strategies cost too much during bull markets.”

“FATT is designed to be able to make money during bull markets while still being able to make money during major market declines. Of course there is no assurance that this will be successful,” Tuttle commented. “This means FATT can be a constant portfolio holding.”

Tail Risk in the Fund’s name refers to the financial risk of an asset or portfolio of assets moving more than three standard deviations from its current price, above the risk of a normal distribution. In a normal bell curve, the most probable returns are concentrated in a bulge at the center of the distribution curve, whereas the less probable, more extreme returns are towards the edges referred to as “tails”. The frequency of market disruptions and volatility have led to “fatter” tails than a normal bell curve might predict. The Fund’s investment strategy is designed to provide positive returns during periods of significant market disruptions.

For more information, please visit FATTAILRISKETF.com

About Tuttle Capital Management
TCM is an industry leader in offering thematic ETFs that utilize informed agility to manage portfolios in a more dynamic manner. As of May 19, 2021, TCM managed thirteen strategies with AUM of $270 million. Please visit www.tuttlecap.com for more information.

Investing involves risk. Principal loss is possible. There is no assurance that a Fund will achieve its investment objective. A Fund’s share price will fluctuate with changes in the market value of its portfolio securities. When you sell your Fund shares, they may be worth less than what you paid for them and, accordingly, you can lose money investing in a Fund. The following risks could adversely affect the net asset value, total return and the value of a Fund and your investment. The risk descriptions below provide a more detailed explanation of the principal investment risks that correspond to the risks described in each Fund’s Summary section of the Prospectus. As an ETF, the fund may trade at a premium or discount to NAV. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. The Fund is new with a limited operating history. Inverse ETFs seek to provide the opposite of the single day performance of the index they track and are subject to substantial volatility.

Investors should carefully consider the investment objectives, risks, charges and expenses of the Fat Tail Risk ETF. This and other important information about the Fund are contained in the prospectus, which can be obtained at www.FATTAILRISKETF.com or by calling 866-904-0406. The prospectus should be read carefully before investing. Fat Tail Risk ETF is distributed by Foreside Fund Services, LLC, member FINRA. Tuttle Capital Management is not affiliated with Foreside Fund Services, LLC.

Media Contact:

Matthew Tuttle

Tuttle Capital Management
(347) 852-0548
[email protected] 

 

Cision View original content:http://www.prnewswire.com/news-releases/fat-tail-risk-etf-to-launch-on-the-nyse-301298206.html

SOURCE Tuttle Capital Management

Posted on

Victory Square Technologies Launches DiscreetCare – a Full-Service Web App for the Treatment of Sensitive & Delicate Medical Issues

VANCOUVER, British Columbia, May 25, 2021 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) announces the launch of DiscreetCare (https://discreetcare.com/) across the United States, as part of its multi-phase expansion into the rapidly growing Telehealth category.

Phase 1 of the DiscreetCare.com web app focuses on treating Hair Loss, Erectile Dysfunction, Premature Ejaculation, Genital Herpes, Cold Sores, Acne, and Bladder Control issues.

Phase 2, launching later this year, will offer at-home testing for STDs, Testosterone and Fertility; as well as treatment for a broader range of sensitive medical issues.

Victory Square Technologies CEO, Shafin Diamond Tejani said, “The vision for DiscreetCare is to be a one-stop provider for what many consider ‘delicate’ medical issues. Our web app gives users access to testing, treatment and prescriptive medicinal remedies – all from the convenience and privacy of one’s mobile device.”

The Company notes that convenience is one of many benefits offered to users of DiscreetCare. DiscreetCare also offers doctor evaluations, and FDA-approved medications with competitive pricing.

VS Digital Health Vice President of Marketing, Binu Koshy, explains, “By offering a service that is both discreet and convenient, we are providing healthcare solutions to those who until now, have chosen ‘avoidance’ over action when it comes to their overall wellbeing. Koshy adds, “Think of that 20-something who just started losing his hair but is too embarrassed to seek treatment, or that 30-year-old with Erectile Dysfunction (ED) who avoids seeking important medical offerings because the Viagra and Cialis commercials typically show and sell to men who are 20 years older.”

DiscreetCare Medical Director, Dr. Jeremy Roebuck adds, “Booking an appointment, sitting in a public waiting room and having an awkward face to face conversation are all roadblocks that contribute to the issue of ‘avoidance’ when it comes to individuals seeking treatment for embarrassing awkward or socially stigmatized conditions.”

DiscreetCare provides an easier and less invasive alternative for its clients… they simply:

1)   Log onto to DiscreetCare.com using your computer or mobile device
2)   Answer a series of medical questions which will be reviewed by a licensed physician,
3)   Receive your medication in discreet packaging within 2 to 4 days.
4)   Follow-up with your doctor, pharmacist or DiscreetCare support if you have any additional questions or concerns

For users wanting a more personal touch or in-depth medical consultation, DiscreetCare will be offering private virtual appointments with a certified doctor from the Company’s vast network of physicians across all 50 states.

Dr. Roebuck explains, “Other digital care platforms provide pre-determined selections assuming the user knows their medical issue. With DiscreetCare, patients can explain symptoms so the doctor can determine their specific condition and prescribe appropriate treatment for the client. For example, a new skin rash could be one of many things, from eczema to psoriasis to a symptom of a more serious underlying condition.”

The COVID-19 pandemic has resulted in more and more people being comfortable receiving medical care from the convenience of their home, turning the concept of Telehealth from a service for early adopters to a fixture across the United States. With the development of their Telehealth platform and nationwide clinician network, Victory Square Technologies has positioned themselves to capitalize on this emerging trend – whether it be further expansion of their own niche services or providing an all-in-one solution for businesses looking to license a white-label virtual care platform and clinician network.

On behalf of the Board of Directors

“Shafin Diamond Tejani”
Director and Chief Executive Officer
Victory Square Technologies Inc.
www.victorysquare.com

For further information about Victory Square, please contact:

Investor Relations
Contact – Edge Communications Group
Email: [email protected]
Telephone: 604 283-9166

Media Relations
Contact – Howard Blank, Director
Email: [email protected]
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed for fast-track growth. VST’s sweet spot is cutting-edge tech that’s shaping the 4th Industrial Revolution. Our corporate portfolio consists of 20 global companies using AI, VR/AR, and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups

VST isn’t your ordinary investor. With real skin in the game, we’re committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you’ll scale and be ready to monetize.

What we do differently for investors

VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF). For investors, we offer early-stage access to the next unicorns before they’re unicorns. Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies. Because we focus on market-ready solutions that scale quickly, we’re able to provide strong and stable returns while also tapping into emerging global trends with big upsides.

For more information, please visit www.victorysquare.com

Forward Looking Statement

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects, offerings and opportunities of Victory Square and its related subsidiaries including VS Digital Health Inc., DiscreetCare.com and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.



Posted on

Superior Plus Outlines the “Superior Way Forward,” a Strategic Roadmap Targeting EBITDA from Operations of $700 Million to $750 Million in 2026

Superior Plus Outlines the “Superior Way Forward,” a Strategic Roadmap Targeting EBITDA from Operations of $700 Million to $750 Million in 2026

TORONTO–(BUSINESS WIRE)–
Superior Plus Corp. (“Superior”) (TSX:SPB) will outline today at its 2021 Investor Day the 2021-2026 strategic roadmap “Superior Way Forward” focused on accelerating growth, improving operational efficiency and maximizing shareholder returns. Our strategic roadmap which we have defined as the Superior Way Forward, is ambitious but we believe it is achievable, and is designed to capitalize on our strengths.

Main Objectives

  • Targeting EBITDA from operations between $700 million and $750 million in 2026
  • Accelerating growth in U.S. Propane Distribution through the planned execution of $1.9 billion of accretive acquisitions
  • Driving additional growth across the entire business through organic growth and operational improvement
  • Differentiating with a digital modernization strategy to position Superior as an optimized, digitally-based logistics business with best-in-class operations and customer experience
  • Focus on disciplined and dynamic capital allocation approach to drive shareholder returns

The key themes of the Superior Way Forward are:

  • Growing through acquisitions – consolidating a highly fragmented U.S. propane market and capitalizing on a robust pipeline of small and medium-scale acquisition opportunities
  • Continuous improvement – optimizing operational efficiency and investing in innovation and technology to drive improvements
  • Organic growth – employing effective sales and marketing programs to drive growth
  • Talent management – continue to attract and retain diverse top talent
  • Commitment to ESG – continued focus on the environment, commitment to safety and employee wellness
  • Strong balance sheet – long-term Total Debt to Adjusted EBITDA Leverage Ratio target of 3.0x to 3.5x and access to low-cost capital

The Superior Way Forward Summary

“We are setting out to become the leader in creating value through differentiation and best-in-class operations in the North American retail propane industry. We envision a Superior Plus that is one of the industry’s most modern and sophisticated businesses, leveraging technology to improve our delivery efficiency and service offering in new and innovative ways,” said Luc Desjardins, President and Chief Executive Officer. “This commitment to innovation and best-in-class operations has uniquely positioned Superior as a buyer of choice in the propane distribution industry and is allowing us to accelerate our growth through the execution of accretive acquisition opportunities.”

Targeting $700 million to $750 million of EBITDA from operations by 2026

Superior has set a goal of achieving EBITDA from operations in the range of $700 million to $750 million in 2026 through acquisitions, continuous improvement, organic growth and an anticipated post-pandemic recovery in commercial volumes. This represents a 10% – 11% EBITDA from operations Compound Annual Growth Rate (“CAGR”) (1) from 2020. In addition, Superior is targeting generating aggregate Free Cash Flow in the range of $2.6 billion to $2.8 billion from 2021 to 2026.

These financial goals are based on Superior’s long-term operating plan and represent performance targets that management is seeking to achieve. They are driven by numerous expectations and assumptions and are subject to certain risks which are outlined in more detail in the forward-looking section below.

2021 Virtual Investor Day

Superior’s Investor Day will be held virtually on Tuesday, May 25, 2021 at 1 PM EDT. The presentation will be broadcast live via webcast with video and will be accessible by web browser. It will also be available on Superior’s website following the event.

Webcast attendees can pre-register to receive the web access information. Attendees may also register on the day of the event.

Event details:

2021 Investor Day – Superior Plus

May 25, 2021

Start: 01:00 p.m. Eastern Time (Toronto / New York)

Please click the registration link below to access the platform.:

https://onlinexperiences.com/Launch/QReg/ShowUUID=3EC7D901-BAE6-4FAE-9FEB-FA8AED30EE4A

(1)

EBITDA CAGR based on EBITDA from operations of $402 million for the year ended December 31, 2020, excluding the Specialty Chemicals segment.

About the Corporation

Superior is a leading North American distributor and marketer of propane and distillates and related products and services, servicing over 780,000 customer locations in the U.S. and Canada.

Forward Looking Information

This press release contains certain forward-looking information within the meaning of applicable Canadian securities laws which is provided for the purpose of presenting information about management’s current expectations and plans. Readers are cautioned that such information may not be appropriate for other purposes. Superior’s actual results could differ materially from those expressed in, or implied by, this forward-looking information, and accordingly, no assurances can be given that any of the results anticipated by the forward-looking information will transpire or occur. Unless otherwise indicated, all figures are presented in Canadian dollars.

Forward-looking information is predictive in nature, depends upon or refers to future events or conditions, or includes words such as “expects”, “anticipates”, “plans”, “predicts”, “believes”, “estimates”, “intends”, “targets”, “projects”, “forecasts”, “goals” or negative versions thereof and other similar expressions or future or conditional verbs such as “may”, “will”, “should”, “would” and “could”. Forward-looking information in this news release includes, without limitation, statements regarding future growth in EBITDA from operations, targeted Free Cash Flow, capital expenditures, targeted Total Debt to Adjusted EBITDA Leverage Ratio; expected acquisition opportunities, acquisition spending, probability of completing acquisitions and achievement of realized synergies from acquisitions; expected reductions in operational expenses; potential annual returns from organic growth; expectations relating to commercial customer recovery; and the future operations, business, financial condition, financial results, priorities, ongoing objectives, strategies and outlook of Superior and its business segments.

Forward-looking information is provided for the purpose of providing information about management’s expectations and plans about the future and may not be appropriate for other purposes. Forward-looking information herein is based on various assumptions and expectations that Superior believes are reasonable in the circumstances, however, they are subject to the risks and uncertainties set forth below and no assurance can be given that these assumptions and expectations will prove to be correct. These assumptions and expectations are based on information currently available to Superior, including information obtained from third party industry analysts and other third party sources, as well as on management’s current plans and its perception of historical trends, the historic performance of Superior’s business segments, current conditions and expected future developments. These assumptions and expectations include, without limitation, anticipated financial performance, current business and economic trends, expected economic growth, the amount of future dividends paid by Superior, Superior’s future dividend policy, business prospects, availability and utilization of tax basis, acquisition opportunities and probability of successfully negotiating and completing acquisitions, achievement of realized synergies from acquisitions, financing availability, absence of any material regulatory developments, currency, exchange and interest rates, weather, trading data and cost estimates. In particular, key assumptions and expectations underlying Superior’s targeted 2026 EBITDA from Operations in the range of $700 million to $750 million and targeted aggregate Free Cash Flow of $2.6 billion to $2.8 billion include the following: 2-3% annual organic growth; $5 million to $15 million in commercial customer recovery from the Covid-19 pandemic; $50 million to $55 million in operating expense improvements; completion of $1.9 billion in acquisitions at multiples consistent with historic multiples for Superior’s acquisitions as well as achieved synergies from acquisitions consistent with historical averages at approximately 25% over the relevant period; no material divestitures; 2021 operating results consistent with Superior’s consolidated 2021 Adjusted EBITDA guidance; and, in respect of the targeted Free Cash Flow, also assumes Adjusted EBITDA in the range of $3.2 billion to $3.5 billion; maintenance capital expenditures in the range of $300 million to $400 million; and lease repayments in the range of $240 million to $250 million over the relevant period. In addition, significant assumptions underlying the consolidated 2021 Adjusted EBITDA guidance referenced above are set forth under the “Financial Outlook” section of Superior’s first quarter MD&A.

By its very nature, forward-looking information involves numerous assumptions, risks and uncertainties, both general and specific. Should one or more of these risks and uncertainties materialize or should underlying assumptions prove incorrect, as many important factors are beyond the control of Superior, Superior’s actual performance and financial results may vary materially from those estimates and expectations contemplated, expressed or implied in the forward-looking information. These risks and uncertainties include incorrect assessments of value and potential synergies when making acquisitions, inability to successfully conclude negotiations and complete acquisitions, competition for acquisition opportunities, increases in debt service charges, the loss of key personnel, fluctuations in foreign currency, exchange rates and commodity prices, variability in cash flows and potential impact on dividends, inadequate insurance coverage, liability for cash taxes, counterparty risk, compliance with environmental laws and regulations, reduced customer demand, operational risks involving our facilities, force majeure, labour relations matters, our ability to access external sources of debt and equity capital, and the risks and assumptions identified in (i) Superior’s first quarter MD&A under the heading “Risk Factors” and (ii) Superior’s most recent Annual Information Form, both of which are filed electronically at www.sedar.com. The preceding list of assumptions, risks and uncertainties is not exhaustive.

When relying on Superior’s forward-looking information to make decisions with respect to Superior, investors and others should carefully consider the preceding factors, other uncertainties and potential events. Any forward-looking information is provided as of the date of this document and, except as required by law, neither Superior nor Superior LP undertakes to update or revise such information to reflect new information, subsequent or otherwise. For the reasons set forth above, investors and others should not place undue reliance on forward-looking information.

Non-GAAP Financial Measures

Throughout this news release, Superior has used the following terms that are not defined by International Financial Reporting Standards (“GAAP”), but are used by management to evaluate the performance of Superior and its businesses. Since non-GAAP financial measures do not have standardized meanings prescribed by GAAP and are therefore unlikely to be comparable to similar measures presented by other companies, securities regulations require that non-GAAP financial measures are clearly defined, qualified and reconciled to their nearest GAAP financial measures. Except as otherwise indicated, these non-GAAP financial measures are calculated and disclosed on a consistent basis from period to period. Specific adjusting items may only be relevant in certain periods. The intent of non-GAAP financial measures is to provide additional useful information to investors and analysts. The measures may also be used by investors, financial institutions and credit rating agencies to assess Superior’s performance and ability to service debt. The measures should not, therefore, be considered in isolation or used in substitute for measures of performance prepared in accordance with GAAP. Other issuers may calculate non-GAAP financial measures differently.

Investors should be cautioned that Adjusted EBITDA, EBITDA from operations and Free Cash Flow should not be construed as alternatives to net earnings, cash flow from operating activities or other measures of financial results determined in accordance with GAAP as an indicator of Superior’s performance.

Superior Non-GAAP financial measures are identified and defined as follows:

EBITDA from operations

EBITDA from operations is defined as Adjusted EBITDA excluding costs that are not considered representative of Superior’s underlying core operating performance, including gains and losses on foreign currency hedging contracts, corporate costs and transaction and other costs. Management uses EBITDA from operations to set targets for Superior (including annual guidance and variable compensation targets). EBITDA from operations is reconciled to net earnings before income taxes. Please refer to the Results of Operating Segments in the Q1 2021 MD&A for the reconciliations.

Adjusted EBITDA

Adjusted EBITDA represents earnings before interest, taxes, depreciation, amortization, losses (gains) on disposal of assets, finance expense, restructuring costs, transaction and other costs, and unrealized gains (losses) on derivative financial instruments. Adjusted EBITDA is used by Superior and investors to assess its consolidated results and ability to service debt. Adjusted EBITDA is reconciled to net earnings before income taxes. Adjusted EBITDA is a significant performance measure used by management and investors to evaluate Superior’s ongoing performance of its businesses. Adjusted EBITDA is also used as one component in determining short-term incentive compensation for certain management employees. The EBITDA of Superior’s operating segments may be referred to as EBITDA from operations. Please see the “Reconciliation of Earnings (Loss) before Income Taxes to Adjusted EBITDA” section of Superior’s Q1 2021 MD&A.

Total Debt to Adjusted EBITDA Leverage Ratio and Pro Forma Adjusted EBITDA

Adjusted EBITDA for the Total Net Debt to Adjusted EBITDA Leverage Ratio is defined as Adjusted EBITDA calculated on a 12-month trailing basis giving pro forma effect to acquisitions and dispositions adjusted to the first day of the calculation period (“Pro Forma Adjusted EBITDA”). Pro Forma Adjusted EBITDA is used by Superior to calculate its Total Net Debt to Adjusted EBITDA Leverage Ratio.

To calculate the Total Net Debt to Adjusted EBITDA Leverage Ratio divide the sum of borrowings before deferred financing fees and lease liabilities by Pro Forma Adjusted EBITDA. The Total Net Debt to Adjusted EBITDA Leverage Ratio is used by Superior and investors to assess its ability to service debt.

Capital Expenditures

Efficiency, process improvement and growth-related expenditures will include expenditures such as acquisition of new customer equipment to facilitate growth, system upgrades and initiatives to facilitate improvements in customer service.

Maintenance capital expenditures will include required regulatory spending on tank refurbishments, replacement of chlorine railcars, replacement of plant equipment and any other required expenditures related to maintaining operations.

Organic Growth

Organic growth calculated as increase in EBITDA from Operations year over year excluding the impact of acquisitions.

Free Cash Flow

Calculated as Adjusted EBITDA less maintenance capital expenditures and capital lease repayments. Free Cash Flow is used by Superior to calculate cash flows available to pay interest and cash taxes, pay dividends, make acquisitions, for capital expenditures and repay debt.

For additional information with respect to financial measures which have not been identified by GAAP, including reconciliations to the closest comparable GAAP measure, see Superior’s Q1 2021 MD&A, available on SEDAR at www.sedar.com

For further information about Superior, please visit Superior’s website at: www.superiorplus.com or contact: Beth Summers, Executive Vice President and Chief Financial Officer, Tel: (416) 340-6015, or Rob Dorran, Vice President, Investor Relations and Treasurer, Tel: (416) 340-6003, E-mail: [email protected], Toll Free: 1-866-490-PLUS (7587).

Beth Summers

Executive Vice President and Chief Financial Officer

Tel: (416) 340-6015

or

Rob Dorran

Vice President, Investor Relations and Treasurer

Tel: (416) 340-6003

E-mail: [email protected]

Toll Free: 1-866-490-PLUS (7587)

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo
Posted on

Juniper Networks Takes Intent Networking to Next Level with New Apstra Software to Simplify Deployment and Day 2 Operations in Even More Data Center Environments

Juniper Networks Takes Intent Networking to Next Level with New Apstra Software to Simplify Deployment and Day 2 Operations in Even More Data Center Environments

Streamlined connectivity and integrations with VMware NSX-T and SONiC help customers to automate and assure the operations of IT, cloud and telco data centers

SUNNYVALE, Calif.–(BUSINESS WIRE)–
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced version 4.0 of Apstra software, the intent-based networking solution acquired earlier in the year. Juniper® Apstra helps organizations to minimize the time and costs associated with deploying and managing traditionally complex data center networks. The new software version builds on the unique multivendor capabilities of the Apstra solution to support VMware NSX-T 3.0 and Enterprise SONiC, in addition to previously supported data center switching from Juniper, Nvidia (Nvidia Cumulus), Arista Networks and Cisco Systems. The Apstra software also has new intent extensions and connectivity templates that provide a more simple and flexible way of connecting attached systems. Additionally, Juniper is offering Apstra with award-winning Juniper Networks® QFX Series switches and SRX Series Services Gateways in proven drop-in “building block” solutions that can seamlessly grow with evolving data center needs.

“Organizations are looking for new ways to enhance the experience of users and operators in the data center,” said Mike Bushong, VP Data Center, Juniper Networks. “Our Apstra software provides the perfect foundation by delivering closed-loop automation, analytics and assurance for intent-based networking across vendors. In operations, speed is nothing without control, and with the newest Apstra extensions and multi-vendor solutions, teams can make changes more quickly with predictable outcomes.”

Apstra Open Extensions and Connectivity Templates

Apstra 4.0 (formerly known as AOS) takes intent-based networking to the next level by extending intent to connections for attached systems. It’s a method of essentially ensuring standardized operations in customized ways. New connectivity templates enable operators to flexibly create their own reusable and validated templates. These facilitate operations with bulk, accurate adds across the entire fabric in minutes, including servers, workloads and devices, while checking that everything in the network is functioning properly. Apstra’s single source of truth knows the intended state of the network and informs operators when anything deviates from expectations.

Additionally, new extensions integrate Apstra software with VMware NSX-T 3.0 and Enterprise SONiC, enabling even more organizations to benefit from Apstra’s reliability and time-savings value. With built-in validation for virtual machine connectivity, Apstra’s NSX-T integration assures and optimizes operation between the virtual and physical networks. Apstra tracks new NSX-T virtual network additions to assure fabric connections are also set up and allows operators to locate virtual machines within the fabric. Furthermore, with Apstra 4.0, Juniper is now the only vendor with commercialsupport for management of Enterprise SONiC. With this new release, Juniper customers have additional options for building cloud-level, large-scale data centers with open networking.

These new integrations complement Juniper’s existing ecosystem of technology partners and underscore the commitment to preserve Apstra as an open and multi-vendor system. Customers can scale with the Apstra software, removing hardware and operational constraints and accelerating data center evolution.

Building Block Solutions

The Apstra 4.0 release focuses on operations across vendors. Additionally, Juniper is making it easier for organizations to build and modernize data centers with Juniper solutions. New turnkey building block solutions combine intent-based networking and Juniper’s industry-leading switches with options for Secure Services Gateways. The scalable, optimized architecture lets teams confidently deploy what’s needed now, as small as a 4-switch deployment, and grow as needed to larger deployments. New data center deployments can be up and running in hours rather than days, using Zero Touch Provisioning (ZTP) and a set of pre-validated blueprints. With these building blocks, small and mid-sized organizations can adopt the most modern and automated data center operations without expansive design projects, lengthy deployment programs and/or extensive in-house data center expertise.

The Data Center Leader

Juniper has been a leader in the Gartner Magic Quadrant for Data Center and Cloud Networking for the past three years. Juniper’s marquee customers include Aston Martin, T-Systems and Zoom. In Q1 2021, Juniper grew its enterprise revenue for a third consecutive quarter, with enterprise orders rising more than 20% Y/Y. Cloud ready data center orders grew nearly 30% Y/Y, as customers continue to recognize the value of Juniper’s cloud ready data center solutions and the differentiation enabled by Apstra.

The Apstra acquisition closed in January 2021.

Supporting quotes:

“We are excited to move forward with Juniper Apstra with the intent that its detailed visibility and troubleshooting abilities in our data center will allow us to find root-cause analysis faster than our current solution. We plan to use customized dashboards to bring visibility to other REI business units regarding the health of the data center.”

– Don Ely, Lead Network Security Engineer, REI

“Intent-based automation and analytics across a variety of network operating stacks, such as Enterprise SONiC, is a key enabler of an open ecosystem. We welcome Juniper’s new Apstra 4.0 offering as it utilizes the advanced capabilities available in Broadcom merchant silicon. By delivering a solution ready for general data center deployments, this combination represents a milestone in spurring SONiC adoption.”

– Hasan Siraj, Head of Software Products and Ecosystem, Core Switching Group, Broadcom

Additional Resources:

About Juniper Networks

Juniper Networks challenges the inherent complexity that comes with networking and security in the multicloud era. We do this with products, solutions and services that transform the way people connect, work and live. We simplify the process of transitioning to a secure and automated multicloud environment to enable secure, AI-driven networks that connect the world. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

Statements in this press release concerning Juniper Networks’ prospects, product availability, future products and expected performance, and expected benefits of our products to users are forward-looking statements within the meaning of the Private Securities Litigation Reform Act that involve a number of uncertainties and risks. Actual results or events could differ materially from those anticipated in those forward-looking statements as a result of certain factors, including delays in scheduled product availability, incompatibility of technologies, the company’s failure to accurately predict emerging technological trends, and other factors listed in Juniper Networks’ most recent report on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. All statements made in this press release are made only as of the date of this press release. Juniper Networks undertakes no obligation to update the information in this release in the event facts or circumstances subsequently change after the date of this press release. Any future product, feature, enhancement or related specification that may be referenced in this press release are for information purposes only, are subject to change at any time without notice and are not commitments to deliver any future product, feature, enhancement or related specification. The information contained in this press release is intended to outline Juniper Networks’ general product direction and should not be relied on in making a purchasing decision.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Category-Data Center

Media Relations:

Leslie Ruble

Juniper Networks

408-936-2111

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Technology Security Other Technology Telecommunications Software Networks Internet Mobile/Wireless Hardware Electronic Design Automation

MEDIA:

Logo
Logo